These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 16884362)
1. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. Jandu N; Richardson M; Singh G; Hirte H; Hatton MW Int J Gynecol Cancer; 2006; 16(4):1536-44. PubMed ID: 16884362 [TBL] [Abstract][Full Text] [Related]
2. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity. Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083 [TBL] [Abstract][Full Text] [Related]
3. Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis. Richardson M; Gunawan J; Hatton MW; Seidlitz E; Hirte HW; Singh G Gynecol Oncol; 2002 Sep; 86(3):279-87. PubMed ID: 12217749 [TBL] [Abstract][Full Text] [Related]
4. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. Walker JB; Nesheim ME J Biol Chem; 1999 Feb; 274(8):5201-12. PubMed ID: 9988770 [TBL] [Abstract][Full Text] [Related]
5. Factors relevant to stimulatory activity of fibrin degradation products in vivo. Thompson WD; Smith EB; Stirk CM; Stout AJ; Kochhar A Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):517-20. PubMed ID: 1723307 [TBL] [Abstract][Full Text] [Related]
6. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis]. Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132 [TBL] [Abstract][Full Text] [Related]
7. Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors. Hatton MW; Southward SM; Ross BL; Clarke BJ; Singh G; Richardson M J Lab Clin Med; 2006 Jan; 147(1):27-35. PubMed ID: 16443002 [TBL] [Abstract][Full Text] [Related]
8. Fibrin degradation and angiogenesis: quantitative analysis of the angiogenic response in the chick chorioallantoic membrane. Thompson WD; Campbell R; Evans T J Pathol; 1985 Jan; 145(1):27-37. PubMed ID: 2578560 [TBL] [Abstract][Full Text] [Related]
9. Degradation of fibrinogen and fibrin by plasmin and nonplasmin proteases in the chronic subdural hematoma: evaluation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot. Nomura S; Kashiwagi S; Ito H; Mimura Y; Nakamura K Electrophoresis; 1993 Dec; 14(12):1318-21. PubMed ID: 8137796 [TBL] [Abstract][Full Text] [Related]
10. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Wilhelm O; Hafter R; Henschen A; Schmitt M; Graeff H Blood; 1990 Apr; 75(8):1673-8. PubMed ID: 2139349 [TBL] [Abstract][Full Text] [Related]
11. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. Hafter R; Klaubert W; Gollwitzer R; von Hugo R; Graeff H Thromb Res; 1984 Jul; 35(1):53-64. PubMed ID: 6474409 [TBL] [Abstract][Full Text] [Related]
12. Electrophoretic demonstration of high molecular weight fibrin degradation products persisting in chronic subdural hematomas. Toyosawa M; Kashiwagi S; Pei W; Fujisawa H; Ito H; Nakamura K Electrophoresis; 1997 Jan; 18(1):118-21. PubMed ID: 9059832 [TBL] [Abstract][Full Text] [Related]
13. Degradation of fibrinogen and cross-linked fibrin by human neutrophil elastase generates D-like fragments detected by ELISA but not latex D-dimer test. Bach-Gansmo ET; Godal HC; Skjønsberg OH Thromb Res; 1998 Nov; 92(3):125-34. PubMed ID: 9806364 [TBL] [Abstract][Full Text] [Related]
14. Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclerotic plaques. Stirk CM; Kochhar A; Smith EB; Thompson WD Atherosclerosis; 1993 Nov; 103(2):159-69. PubMed ID: 7507326 [TBL] [Abstract][Full Text] [Related]
16. Characterization of peptides cleaved by plasmin from the C-terminal polymerization domain of human fibrinogen. Southan C; Thompson E; Panico M; Etienne T; Morris HR; Lane DA J Biol Chem; 1985 Oct; 260(24):13095-101. PubMed ID: 2932434 [TBL] [Abstract][Full Text] [Related]
17. Hemostatic findings of pleural fluid in dogs and the association between pleural effusions and primary hyperfibrino(geno)lysis: A cohort study of 99 dogs. Zoia A; Drigo M; Piek CJ; Simioni P; Caldin M PLoS One; 2018; 13(2):e0192371. PubMed ID: 29462172 [TBL] [Abstract][Full Text] [Related]
18. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. Thompson WD; Smith EB; Stirk CM; Marshall FI; Stout AJ; Kocchar A J Pathol; 1992 Sep; 168(1):47-53. PubMed ID: 1280677 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of hemostatic and fibrinolytic markers in dogs with ascites attributable to right-sided congestive heart failure. Zoia A; Augusto M; Drigo M; Caldin M J Am Vet Med Assoc; 2012 Nov; 241(10):1336-43. PubMed ID: 23113526 [TBL] [Abstract][Full Text] [Related]
20. Hemostatic Findings in Ascitic Fluid: A Cross-Sectional Study in 70 Dogs. Zoia A; Drigo M; Piek CJ; Simioni P; Caldin M J Vet Intern Med; 2017 Jan; 31(1):43-50. PubMed ID: 27862300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]